Find a Research Expert

Experts
 Menu

Norma O'Donovan

Institution

Dublin City University

Contact

Subjects

Biochemistry

Pharmacology

Details
Publications 59
As first author 3
As last author 16
Unique topics 346
Collaborations 94
Patents 1
Sources 7
Are you Norma O'Donovan? Click here to provide feedback on your profile.
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
Earlier
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
Earlier

2019

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
2019

Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.
2019

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
2018

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
2018

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
2018

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
2017

Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
2017

Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
2017

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
2017

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
2017

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
2017

Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells.
2017

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
2017

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
2017

Vitamin D receptor as a target for breast cancer therapy.
2016

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.
2016

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
2016

Pre-clinical evaluation of the AR inhibitor enzalutamide in triple negative breast cancer cells.
2016

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
2016

Validated biomarkers: The key to precision treatment in patients with breast cancer.
2016

Vitamin D analogues: Potential use in cancer treatment.
2015

ADAM10: a new player in breast cancer progression?
2015

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
2015

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
2014

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
2014

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
2014

Predictive biomarkers for dasatinib treatment in melanoma
2014

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
2013

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.
2013

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
2013

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
2012

EGFR and HER2 inhibition in pancreatic cancer.
2012

Structure--activity relationship and mode of action of N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters: novel organometallic anticancer compounds.
2012

The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.
2011

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines
2011

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
2011

Src: a potential target for the treatment of triple-negative breast cancer.
2011

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
2010

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.
2010

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
2010

Prospects for non-immunological molecular therapeutics in melanoma.
2010

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
2010

Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agents
2009

Alterations in integrin expression modulates invasion of pancreatic cancer cells
2009

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
2009

HER-2 signaling and inhibition in breast cancer.
2009

Identification of pancreatic cancer invasion-related proteins by proteomic analysis
2009

Role of ADAMs in cancer formation and progression.
2009

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
2008

Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells
2008

Identification of pancreatic cancer invasion-related proteins by proteomic analysis.
2008

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
2007

Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
2007

EGFR and HER-2 antagonists in breast cancer.
2007

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
2006

Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays.
2004

Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.
2004

Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes.
2003

Caspase 3 in breast cancer.

These arethe7 unique sources for Norma O'Donovan's 59 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Dublin City University 49
Ireland -> Dublin City University -> PubMed 46
Ireland -> Maynooth University 4
Ireland -> Royal College of Surgeons in Ireland 1
Ireland -> Trinity College Dublin 7
Ireland -> University College Dublin 6
Ireland -> University College Dublin -> PubMed 5
Sep 10, 2009

DETECTION AND TREATMENT OF AN INVASIVE CANCER PHENOTYPE
+

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.